A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib
Status:
Terminated
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
This study evaluate activity and safety profile of weekly Genexol-PM in patients with
advanced hepatocellular carcinoma for whom sorafenib treatment failed. Patients will receive
Genexol-PM on days 1, 8, and 15 every 4 weeks.